The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study

Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, Kabeer Ali, Kathryn Grimaldos, Gabriella Grimaldos, Abhinav Karan, Rajeev Seecheran, Valmiki Seecheran, Sangeeta Persad, Harun Abdullah, Lakshmipathi Peram, Stanley Giddings, Shastri Motilal, Antonio Tello-Montoliu, David Schneider, Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, Kabeer Ali, Kathryn Grimaldos, Gabriella Grimaldos, Abhinav Karan, Rajeev Seecheran, Valmiki Seecheran, Sangeeta Persad, Harun Abdullah, Lakshmipathi Peram, Stanley Giddings, Shastri Motilal, Antonio Tello-Montoliu, David Schneider

Abstract

Introduction: This prospective pharmacodynamic (PD) study aimed to assess the effect of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin on platelet reactivity.

Methods: Patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) (n = 20) who were actively treated with dual antiplatelet therapy (DAPT) of aspirin 81 mg daily and clopidogrel 75 mg daily were recruited. Platelet function was measured with the VerifyNow™ P2Y12 assay (Instrumentation Laboratory, Massachusetts, USA) and assessed before the initiation of and after 10 days of treatment with empagliflozin 25 mg once daily maintenance dose regimen. Results were compared with a paired t test.

Results: The mean P2Y12 reaction units (PRU) on empagliflozin was significantly less than without empagliflozin at baseline (187.35, 95% confidence interval (CI) 155.38-219.32 vs. 217.25, CI 180.60-253.90; p < 0.030). The mean difference in PRU was 29.90 (95% CI 3.17-56.63). No patients experienced any serious adverse events (SAEs).

Conclusions: Significantly attenuated platelet reactivity was observed on empagliflozin as compared to without empagliflozin. This dedicated pharmacodynamic study could be clinically pertinent for Trinidadian patients with stable CAD and T2DM on DAPT. Further studies are required to confirm these exploratory findings. (Funded by the University of the West Indies, St. Augustine; EFFECT).

Clinical trial registration: ClinicalTrials.gov number NCT04342819.

Keywords: Empagliflozin; Platelet function; Platelet reactivity; Sodium–glucose cotransporter 2 inhibitor (SGLT2i); VerifyNow™.

Figures

Fig. 1
Fig. 1
Methodology outline
Fig. 2
Fig. 2
Comparison of patients’ P2Y12 reaction units (PRU) before and after empagliflozin 25 mg

References

    1. Das SR, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020 doi: 10.1016/j.jacc.2020.05.037.
    1. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.
    1. Nassif ME, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction. Circulation. 2019;140:1463–1476. doi: 10.1161/CIRCULATIONAHA.119.042929.
    1. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–225. doi: 10.1007/s00125-016-4157-3.
    1. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–2117. doi: 10.1007/s00125-018-4670-7.
    1. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053.
    1. Seecheran NA, et al. Prevalence of clOpidogrel ‘resIstaNce’ in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. Open Heart. 2019;6:e000841. doi: 10.1136/openhrt-2018-000841.
    1. Seecheran N, et al. TRimetazidine as an Agent to affeCt clopidogrEl Response: the TRACER study. Cardiol Ther. 2019 doi: 10.1007/s40119-019-0139-0.
    1. Seecheran N, et al. The effect of low-dose ticagrelor on platelet function profiles in patients with stable coronary artery disease in Trinidad: the TWIST pilot study. Cardiol Ther. 2020 doi: 10.1007/s40119-020-00195-2.
    1. Tantry US, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–2273. doi: 10.1016/j.jacc.2013.07.101.
    1. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–527. doi: 10.2337/dc08-1865.
    1. Ali A, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice. Diabetes Ther. 2019;10:1595–1622. doi: 10.1007/s13300-019-0657-8.
    1. Madaan T, Husain I, Akhtar M, Najmi AK. Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose cotransporter 2 inhibitors. Clin Exp Pharmacol Physiol. 2018 doi: 10.1111/1440-1681.12963.
    1. Holman RR, Paul SK, Angelyn Bethel M, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161–174. doi: 10.2147/DMSO.S233538.
    1. Winocour PD, Watala C, Kinglough-Rathbone RL. Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects. Thromb Haemost. 1992;67:567–571. doi: 10.1055/s-0038-1648495.
    1. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92:1362–1365. doi: 10.1016/j.amjcard.2003.08.033.
    1. Assert R, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44:188–195. doi: 10.1007/s001250051598.
    1. Pedreño J, Hurt-Camejo E, Wiklund O, Badimaón L, Masana L. Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very—low-density lipoprotein particles. Metabolism. 2000;49:942–949. doi: 10.1053/meta.2000.6742.
    1. Yngen M, Norhammar A, Hjemdahl P, Håkan Wallén N. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes Vasc Dis Res. 2006;3:52–56. doi: 10.3132/dvdr.2006.008.
    1. Scheen AJ. Reduction in HbA1c with SGLT2 inhibitors vs DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials. Diabetes Metab. 2020;46:186–196. doi: 10.1016/j.diabet.2020.01.002.
    1. Storgaard H, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11:e0166125. doi: 10.1371/journal.pone.0166125.
    1. Ranucci M, et al. Platelet reactivity in overweight and obese patients undergoing cardiac surgery. Platelets. 2019;30:608–614. doi: 10.1080/09537104.2018.1492108.
    1. Vasilakou D, et al. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274. doi: 10.7326/0003-4819-159-4-201308200-00007.
    1. Westerbacka J, et al. Inhibition of platelet-collagen interaction. Arterioscler Thromb Vasc Biol. 2002;22:167–172. doi: 10.1161/hq0102.101546.
    1. Hammoudi N, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233–246. doi: 10.1007/s10557-017-6734-1.
    1. Xu L, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149. doi: 10.1016/j.ebiom.2017.05.028.
    1. Nishimura N, et al. Ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol. 2016;51:1141–1149. doi: 10.1007/s00535-016-1200-6.
    1. Komiya C, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One. 2016;11:e0151511. doi: 10.1371/journal.pone.0151511.
    1. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 2008;28:s11–s16. doi: 10.1161/ATVBAHA.107.159178.
    1. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120:713–735. doi: 10.1161/CIRCRESAHA.116.309326.
    1. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070. doi: 10.1161/CIRCRESAHA.110.223545.
    1. Handin RI, Karabin R, Boxer GJ. Enhancement of platelet function by superoxide anion. J Clin Investig. 1977;59:959–965. doi: 10.1172/JCI108718.
    1. Schaeffer G, Wascher TC, Kostner GM, Graier WF. Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia. 1999;42:167–176. doi: 10.1007/s001250051135.
    1. Schafer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008;6:52–60. doi: 10.2174/157016108783331295.
    1. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109(21):2524–8. doi: 10.1161/01.CIR.0000129773.70647.94.
    1. Tahara A, et al. Effects of sodium-glucose co-transporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975–987. doi: 10.1111/jphp.12223.
    1. Seecheran N, et al. Epidemiologic insight into Trinidad’s awareness and prevention of heart disease. The EPITAPH study - a Trinidadian cardiovascular health literacy survey. Int J Community Med Public Health. 2017;4:903. doi: 10.18203/2394-6040.ijcmph20171305.
    1. Seecheran N, et al. A Trinidadian cardiovascular medication adherence survey: the ADHERE TNT study. Int J Community Med Public Health. 2017;4:3601. doi: 10.18203/2394-6040.ijcmph20174218.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe